Profile of patients with Thrombosis evaluated in a Tertiary Care Center. by Aysha Ali, A
1 
 
PROFILE OF PATIENTS WITH THROMBOSIS 
EVALUATED IN A TERTIARY CARE CENTER 
 
DISSERTATION 
 
 
SUBMITTED FOR 
M.D. IN  PATHOLOGY 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
 
 
 
 
 
 
 
 
 
DEPARTMENT 
OF PATHOLOGY 
PSG INSTITUTE OF MEDICAL SCIENCE & RESEARCH 
PEELAMEDU, COIMBATORE – 641 004. 
TAMILNADU, INDIA 
FEBRUARY – 2009. 
 
 
 
 
 
 
 
 
2 
 
 
CERTIFICATE 
 
 This is to certify that the dissertation work entitled 
“PROFILE OF PATIENTS WITH THROMBOSIS EVALUATED 
IN A TERTIARY CARE CENTER” submitted by Dr. Aysha Ali is 
work done by her during the period of study in this department from June 
2006 to February 2009. This work was done under the guidance of Dr. 
Prasanna N. Kumar, Professor, Department of Pathology PSG IMS & 
R. 
 
 
 
 
Dr. Alamelu Jayaraman    Dr. 
S.Ramalingam 
Professor & Head of the Department   Principal 
Department of Pathology     PSG IMS & R 
PSG IMS & R      Coimbatore  
Coimbatore – 641 004 
 
 
 
 
 
 
 
3 
 
 
ACKNOWLEDGEMENT 
 It gives me immense pleasure to express my deep gratitude 
and heartfelt thanks to my respected teacher and guide Dr.Prasanna N. 
Kumar, Professor, Department of Pathology, PSG IMS & R for her 
invaluable guidance, immense patience and timey advice.  
I express my sincere thanks to Dr. Alamelu Jayaraman, Professor 
and Head of the Department of Pathology, PSG IMS & R for her 
suggestions, encouragement and moral support. 
I express my humble thanks to all faculty members of the 
department of Pathology, PSG IMS & R whom I have had the privilege to 
work with, especially Professor Dr. V.Nirmala, Associate Professors Dr.                         
S. Shanthakumari, Dr. T.M.Subba Rao and Dr. Vanitha.S, Assistant 
Professors Dr.Suma. B.Pillai, Dr. M. Kanmani, Dr. Uma 
Maheswari,Dr.Rajesh and Dr. Divya Naik. 
I am also very thankful to Dr. Ram Ganesh and Dr. Rajeswari who 
have been a source of strength in my research pursuit. 
I am extremely greatful to Mrs. Asha.K and other Technical Staff 
of Clinical Pathology Section for their kind cooperation.  
I am obliged to all patients who contributed to my study and 
findings.  
4 
 
 
CONTENTS 
 
         PAGE 
NO 
 
CERTIFICATE 
ACKNOWLEDGEMENT 
1. INTRODUCTION      1- 3 
2. AIMS AND OBJECTIVES         4  
3. MATERIALS AND METHODS   5- 18 
4. REVIEW OF LITERATURE    19 - 43 
5. RESULTS       44 - 55 
6. DISCUSSION      56 - 69 
7. SUMMARY AND CONCLUSIONS   70 - 73 
8. BIBLIOGRAPHY 
9. MASTER CHART 
10. KEY TO MASTER CHART 
 
 
 
 
 
5 
 
 
                                 INTRODUCTION 
 
A delicate balance exists between fibrin formation and fibrinolysis in 
vivo. Reduced blood flow, changes in the vessel wall and changes in blood 
composition result in disturbance of this balance, which favors fibrin formation 
and ultimately lead to formation of occlusive thrombi. 
 
Venous and arterial thrombosis are common diseases with an estimated 
incidence of 1 in 1000 individuals per year50 .Despite the growing insight in the 
pathogenesis of thrombophilia, the cause of many thrombotic episodes remain 
unknown. Although the causes are not always identified, several risk factors 
have been studied and it was observed that hypercoagulability is one of the 
triggers that alters the hemostasis. Hypercoagulability may occur due to 
defective naturally occurring anticoagulant mechanisms or due to heightened 
levels of procoagulant factors. Several risk factors have been identified like 
increased levels of coagulation factors-factor VIII, IX, XI, II and fibrinogen 
which are cumulatively explored by activated partial thromboplastin time used 
over the last 50 years as a standard screening test in clinical laboratories 
throughout the world. Several groups have identified elevated levels of factor 
VIII as an independent risk. 
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        Antiphospholipid antibody syndrome is a clinical entity with a 
strong tendency for thrombosis accompanied by high mortality and morbidity. 
It is characterized by persistently elevated levels of antibodies directed against 
anionic phospholipids. As a result of antibodies homeostatic regulation of 
blood coagulation is altered. The diagnosis is made when arterial or venous 
thrombosis or recurrent pregnancy failure occurs in a patient  with a laboratory 
test result persistently positive for an antiphospholipid antibody. 
 
          Paroxysmal nocturnal hemoglobinuria is a disease due to clonal 
disorder of the hematopoietic stem cell. This disorder is characterized by 
increased sensitivity to complement mediated lysis which affects  all blood 
cells including platelets, which  results in an increased sensitivity to venous 
thrombosis. 
 
       Sickle cell disease is an inherited disorder characterized by the 
presence of sickle hemoglobin which results from substitution of glutamic acid 
by valine at the sixth position of beta globin chain. Nearly every component of 
hemostasis including platelet function, procoagulant, anticoagulant and 
fibrinolytic system is altered and is associated with an increased risk of venous 
and arterial thrombosis. 
 
This study is aimed at identifying the acquired risk factors of  
thrombosis like antiphospholipid antibody syndrome, elevated factor VIII level, 
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shortened  activated partial thromboplastin time , paroxysymal nocturnal 
hemoglobinuria and sickle cell disease, so that  the patients at risk can be 
identified and prevented from the occurrence of thrombosis. Previous studies 
have been done mostly in the European population, so this study also aims in 
identifying the risk factors involved in the pathogenesis of thrombosis in Indian 
population. It is also aimed in evaluating the investigations of antiphospholipid 
antibodies. 
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AIMS AND OBJECTIVES 
 
1. To examine the risk factors involved in the pathogenesis of 
thrombosis in the Indian population.  
2. To investigate the significance of these risk factors in the  
incidence of venous and arterial thombosis. 
3. To evaluate investigations for the diagnosis of antiphospholipid  
antibodies.  
4. To evaluate the significance of two different antiphospholipid 
antibodies – lupus anticoagulant and anticardiolipin 
           antibodies in the pathogenesis of thrombotic disorders. 
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MATERIALS AND METHODS 
 
Blood samples were collected from patients presenting with the clinical 
picture of arterial or venous thrombosis to the Departments of Cardiology, 
Neurology, Orthopaedics, Obstetrics & Gynaecology and Dermatology. 2.7 ml 
of blood was collected in tubes containing 0.3 ml of 3.2% trisodium citrate 
(ratio of 9:1); 2 ml in plain tubes for serum and 3 ml in tubes containing 1 ml of 
EDTA (Ethylene Diamine Tetra Acetic acid). The following investigations 
were done on the blood samples: 
 
Complete blood count 
Sickling test 
Ham’s acidified serum test  
Sucrose lysis test 
Screening tests for coagulation   
Prothrombin time 
Activated partial thromboplastin time 
Lupus anticoagulant assay (dRVVT based) 
Factor VIII:c (one-stage aPTT based) assay 
Anticardiolipin anibody 
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         20 control samples were run for lupus anticoagulant, 
antiphospholipid antibody and APTT and all the values were within normal 
limits. The statistical analyses of the results were done using a chi-square. 
 
1. COMPLETE BLOOD COUNT 
 
This was done using the patient’s EDTA blood sample on a Beckman 
Coulter which is a 26 parameter fully automated hematology analyzer with five 
part leukocyte differential count.  
 
2. SICKLING TEST 
 
  This was done using the Sicklevue test kit manufactured by Tulip 
diagnostics. 
 
PRINCIPLE: 
 
This test is based on the solubility difference between HbS and HbA in 
concentrated buffer solution. Red blood cells under test are lysed by a powerful 
hemolytic agent and the released hemoglobin is then reduced by sodium 
dithionate in a concentrated phosphate buffer. HbS precipitates in the presence 
of sodium dithionate causing turbidity of the reaction mixture, which is easily 
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visualized. Under the same conditions, HbA as well as most other hemoglobins 
are soluble, they remain in solution resulting in a clear suspension.  
 
MATERIALS NEEDED: 
 
Patients and control EDTA anticoagulated blood, solubility test reagent 
(concentrated phosphate buffer solution containing red cell lysing agent), 
empty reaction tubes, 2 ml pipettes, test tube, stopwatch, laboratory centrifuge. 
 
METHOD: 
 
All reagents and samples are brought to room temperature before use. 
The reaction tubes are labeled appropriately and set on a test tube rack. 100 µl 
of EDTA anticoagulated blood sample from the patient is added to 2 ml of the 
solubility test reagent (concentrated phosphate buffer solution containing red 
cell lysing agent). This is mixed for 10 seconds and allowed to stand for 10 
minutes. The tubes are then centrifuged at 1200 g for 5 minutes. The pattern 
formed in the reaction tubes is observed. A control is also run simultaneously 
by using a normal subject’s sample. 
                                                                                                        
INTERPRETATION 
In normal people (Hb-AA) the lower layer will be clear and dark red in colour 
and upper layer will have a grey precipitate. 
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In sickle cell anemia (Hb-SS), the lower layer will be colourless and 
upper layer will have red precipitate.  
In sickle cell trait (Hb-AS), the lower layer will be clear and light red to 
pink in colour while the upper layer shows red precipitate.  
 
3. SUCROSE LYSIS TEST 
 
PRINCIPLE: 
The principle of this test is that red cells absorb complement 
components from serum at low ionic concentrations. Red cells from cases of 
paroxysmal nocturnal hemoglobinuria undergo lysis because of their greater 
sensitivity to lysis.  
 
MATERIALS REQUIRED: 
 
  50% Suspension of patient’s red cells, isoosmotic solution of 
sucrose (92.4 g/l), fresh normal ABO compatible serum, normal saline, 
spectrophotometer. 
 
PROCEDURE: 
 
An isoosmotic solution of sucrose is required (92.4 g/l). This can be 
stored at 4 degree Celsius upto 2-3 weeks. 
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Two tubes are set up, one containing 0.05 ml of fresh normal ABO 
compatible serum diluted in 0.85 ml of sucrose solution and the other 
containing 0.05 ml of fresh normal serum diluted in 0.85 ml of saline. To each 
tube 0.1 ml of 50% suspension of washed red cells is added. The tubes are 
incubated at 37° Celsius for 30 minutes, centrifuged and observed for lysis. The 
quantum of lysis is measured using a spectrophotometer. 
 
INTERPRETATION: 
 
In paroxysmal nocturnal hemoglobinuria, 10-80% lysis is observed. 
<10% lysis may be seen in certain leukemias and myelosclerosis.10 
 
4. HAM’S ACIDIFIED SERUM TEST 
 PRINCIPLE:  
 
Patient’s red cells obtained from EDTA or defibrinated blood are 
exposed at body temperature to the action of fresh normal serum acidified to 
optimum pH for lysis (pH 6.5-7.0).  
METHOD: 
 
0.5 ml samples of fresh normal AB group serum or serum that is ABO 
compatible with the patient’s blood are delivered into six test tubes. Two of the 
tubes are placed at 56° C for 10-30 minutes in order to inactivate complement. 
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The other two pairs are kept at   room temperature and 0.05 ml of 0.2 ml/l 
hydrochloric acid is added. Similar volumes of acid are added to the inactivated 
serum samples. All the tubes are incubated at 37°C. 50% suspensions of 
washed patient’s and control red cells are added  to the tubes containing 
unacidified fresh serum, acidified fresh serum and acidified inactivated serum. 
These tubes are then incubated at 37° C for 1 hour. The tubes are centrifuged 
after incubation. 
 
INTERPRETATION: 
 
In a patient with paroxysmal nocturnal hemoglobinuria, lysis is seen in 
the tube containing acidified serum. There is no lysis in the tube containing 
non-acidified or heat inactivated serum. The control cells do not undergo lysis 
in any of the three test tubes.  The percentage of lysis may be measured using a 
spectrophotometer at a wavelength of 540 nm. 
 
5. PLASMA CLOTTING TESTS 
 
a.  Equipment – STAGO coagulation analyzer, water bath, 
centrifuge, freezer, pipettes, glassware and disposable plastic tubes, timers. 
b.  Reagents include tissue thromboplastin, APTT reagent, calcium 
chloride, anticoagulants, pooled plasma, reference plasma and factor deficient 
plasma. 
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c.  Samples - Blood from both controls and patients was collected by 
clean venipuncture, using a 21 guage needle, into a tube containing 3.2% 
trisodium citrate in a ratio of nine parts blood to one part citrate. The samples 
were centrifuged at 1500g for 15 minutes to prepare platelet poor plasma 
(PPP). For the lupus anticoagulant and anticardiolipin tests which were not 
done immediately the plasma was removed into plastic tubes, centrifuged a 
second time at 1500 g for 15 minutes and aliquots of this platelet–depleted 
plasma were stored at -80° C until testing. The platelet count of the platelet 
depleted plasma was < 5 X 109/ L. 
d.  Anticoagulants - 3.2% sodium citrate in a ratio of 1 part 
anticoagulant to 9 parts of blood for clotting tests.  
 
A. PROTHROMBIN TIME 
 
PRINCIPLE:  
 
The prothrombin time is the time taken for citrated plasma to clot on the 
addition of tissue thromboplastin and calcium chloride. It measures the 
extrinsic and common pathways i.e. Factors I, II, V, VII and X. 
 
The source of tissue thromboplastin varies and may be from human or 
animal brain, placental extract or recombinant. In this test freeze dried 
thromboplastin derived from rabbit cerebral tissues was used.  The 
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International Sensitivity Index of the thromboplastin reagent that was used for 
this study was 1.21. The reagent comes mixed with calcium chloride.  
 
METHOD: 
 
The test is performed at 370C, mixing one part of plasma with two parts 
of the reagent calcium chloride mixture and timing the plasma clot formation. 
A normal control is done each time. Every test is run in duplicate. The normal 
PT by this technique is 11 – 16 seconds. A greater than 2 seconds difference 
from the control is considered significant.  
 
B. ACTIVATED PARTIAL THROMBOPLASTIN TIME 
 
PRINCIPLE: 
 
Activated partial thromboplastin time is the time taken for citrated 
plasma to clot on the addition of a surface activator, phospholipid and calcium 
chloride. APTT measures the Intrinsic and Common pathways. It measures 
Factors I, II, V, VIII, IX, X, XI, and XII. It does not measure FVII and FXIII 
activity. 
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The activators used are kaolin, silica, celite, actin or ellagic  acid.  The 
activator used in this study is silica. The partial thromboplastin is 
phospholipids. 
 
Lupus anticoagulant exerts an inhibitory effect on phospholipids which 
are required in the clotting pathways, Hence the presence of lupus 
anticoagulants prolongs clotting time.  
 
METHOD: 
 
Lupus sensitive APTT reagent which is commercially available as a 
freeze dried preparation containing cephalin and a particulate activator (silica) 
in a buffered medium is used.  
 
One part of plasma is mixed with one part of activator and phospholipid, 
incubated at 370C and one part of calcium chloride is added and the time to clot 
is noted. 
 
INTERPRETATION: 
The normal APTT by this method is 28 - 35 seconds. A greater than 5 seconds 
difference from the control is considered abnormal. A shorter than normal 
APTT indicates an activated sample or a hypercoagulable state.  
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CORRECTION STUDIES: 
 
When the APTT is prolonged, correction studies are done to 
differentiate whether the prolongation is due to an inhibitor or a factor 
deficiency. This is done by mixing equal volumes of the test plasma and 
control pool plasma and repeating the test. When inhibitors are present the 
prolonged timing will not correct.  
 
6.  LUPUS ANTICOAGULANT ASSAY (dRVVT based): 
   
PRINCIPLE: 
Russell’s viper venom activates factor X in the presence of   
phospholipid and calcium ions. Lupus anticoagulant prolongs the clotting time 
by binding to phospholipid and preventing the action of Russell’s viper venom.  
 
MATERIALS REQUIRED: 
 
Platelet poor plasma- from patient and control Glyoxaline buffer, 
Russell’s viper venom (lyophilized), calcium chloride 0.025 mol/l, 
phospholipid. 
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METHOD: 
 
  This test is performed at 37°C, mixing one part of platelet poor 
plasma to one part of a lyophilized preparation of Russell’s viper venom and 
phospholipids and one part of 0.025M calcium chloride and timing the plasma 
clot formation. This is the ‘screen time’ which should be normally 28-45 
seconds.  
 
When the screen time is more than 45 seconds, the test is repeated using 
the Lupus Anticoagulant Confirm kit, which contains excess of   phospholipids. 
 
INTERPRETATION: 
  
Ratios of mean screen time/mean confirm time <1.0 is normal. 
In this study, if the screen time and confirm time is more than 45 
seconds and the ratio between screen and confirm is more than 1 , then it was 
labeled as lupus anticoagulant positive. 
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7. ANTICARDIOLIPIN ANTIBODY TEST:  
 
PRINCIPLE:  
 
Cardiolipin IgA, IgM, IgG kits are available for determination of 
autoantibodies directed against cardiolipin in human serum.  The kits used are 
solid phase enzyme immunoassays. Microtitre wells are coated with cardiolipin 
and β2 –glycoprotein 1. The presence of cardiolipin and β2 –glycoprotein 1 
complexes allows specific cardiolipin antibodies to bind to the solid phase. 
  
MATERIALS REQUIRED: 
 
Microtitre plate reader with 450 nm reading filter 
Microplate washing device 
Microtitre plates-12×8 well strips with breakaway microwells 
Calibrators- containing diluted human serum and sodium azide as 
preservative 
Conjugates-15ml IgG, 15ml IgM (anti-human immunoglobulins 
conjugated to horseradish peroxidases), TMB substrate-15 ml(stabilized 
hydrogen peroxide), stop solution- 1M hydrochloric acid, 
Sample buffer –containing trisodium chloride, sodium azide, BSA, wash 
buffer containing tris, sodium chloride, tween, and sodium azide  
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METHOD: 
Antigen precoated microplate wells are incubated with calibrators, 
controls and serum specimens. During the incubation, antibody present in the 
test sample binds to coated wells. The wells are then washed to remove 
unbound antibodies and horse radish peroxidase labeled anti-human Ig is 
incubated into the wells. Chromogen is added and autoantibodies are measured 
using a spectrophotometric plate reader using a 450 nm filter. 
 
INTERPRETATION:  
 
Calibration curves are made with the absorbance value at 450/630 nm 
on the Y axis and the cardiolipin class specific Ig on the X axis. The 
concentration of anticardiolipin class specific antibody is read from the 
calibration curve. Values > 15 MPL/ml for IgM and >15 GPL/ml for IgG 10 
was labeled as positive 
 
8. FACTOR VIII ASSAY: 
 
PRINCIPLE: 
 
The principle of the assay is based on the ability of reference plasma and 
the test plasma to correct the prolonged APTT of plasma deficient in the one 
factor that is being assayed – in this case Factor VIII. For the assay, reference 
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plasma with known content of all the factors and factor VIII deficient plasma 
with factor level less than 1% activity must be available. 
 
MATERIALS REQUIRED: 
 
STAGO coagulation analyzer, APTT reagent (STAGO CK PREST), 
Owren Koller buffer, calcium chloride 0.025 M, system control plasma- normal 
and abnormal, Factor VIII deficient plasma (Stago) 
  
METHOD:  
 
One part of test plasma is mixed with one part of factor VIII deficient 
plasma and one part of APTT reagent, incubated at 370C, one part of calcium 
chloride is added and the time taken to clot is noted. 
 
Abnormal system controls with a Factor VIII level of 32 – 46% and 
normal system controls with Factor VIII level of 87-121% are subjected to the 
test simultaneously with patient’s sample. 
 
INTERPRETATION: 
Factor VIII level is expressed as percentage of the activity of normal 
plasma. 
Normal levels are 50- 150%10 
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REVIEW OF LITERATURE 
 
Thrombosis may be defined as formation and propagation of blood clot 
within the vasculature56. When a blood vessel is damaged and normal 
endothelial cell barrier is disrupted platelets are recruited from the blood vessel 
to the site of damage to form an occlusive plug. This is by adhesion and 
aggregation mediated by von Willebrand factor and fibrinogen 
 
                  After the formation of primary hemostatic plug, the 
coagulation system is triggered when factor VIII combines with tissue factor 
leading to step wise activation of a series of proenzymes to produce thrombin. 
Thrombin activates platelets leading to exposure of negatively charged 
phospholipids which leads to clotting factor assembly further helping in 
thrombin formation. Thrombin clots fibrinogen to fibrin which is then 
crosslinked and anchored into place by process of clot retraction. Thus, clot 
formation is mediated by adhesive proteins and their receptors and proenzymes 
and their activators. This process is regulated by antithrombin III, 
thrombomodulin and protein C, protein S system which inactivate accelerator 
of thrombin formation (Factor Va and factor VIIIa). Subsequently clot is lysed 
by plasmin formation by the fibrinolytic system17. 
 
                 There is a balance between fibrin formation and fibrinolysis. 
Decreased blood flow, changes in vessel wall and hypercoagulability may lead 
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to disturbance of this balance which favors fibrin formation and formation of 
occlusive thrombi17. Venous thrombi occur as a result of clot formation in a 
vein due to decreased blood flow. Arterial thrombosis occurs due to formation 
of platelet aggregates at the site of vessel wall injury9. 
 
   The causes of arterial and venous thrombosis can be hereditary or 
acquired. The hereditary causes are antithrombin III deficiency, protein C 
deficiency, protein S deficiency, dysfibrinogenemia, elevated lipoprotein 
levels, elevated factor VIII levels etc. Acquired causes described  
are antiphospholipid antibody syndrome, paroxysmal nocturnal 
hemoglobinuria, malignancies, myeloproliferative disorders, autoimmune 
hemolytic anemia, nephrotic syndrome, pregnancy, immobiliztion etc 17,23,32,44. 
     
          When approaching a patient with a thrombophilic disorder, it will 
be useful to differentiate between patients with acquired and hereditary 
hypercoagulable states. Hereditary disorders are often attributed to a single 
mutation of protein in a critical anticoagulant pathway, whereas acquired 
hypercoagulable states consist of a heterogenous group of disorders that are 
associated with an increased tendency towards thrombotic complications 32, 56. 
A complete history and physical examination is necessary while evaluating 
patients with thrombosis4,57. 
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        An individual can be labeled strongly or weakly thrombophilic 
based on history. A strongly thrombophilic patient will have three important 
features5- 
 
1. First thromboembolic event occurring prior to the age of 50 
2. History of recurrent thrombotic episodes 
3 A first degree relative with a documented venous 
thromboembolic event prior to age of 50. 
 
  A strongly positive individual should have full laboratory 
investigation for thrombophilia like-factor V, homocysteine antiphospholipid 
antibody, protein C, protein S and a weakly positive individual should be 
investigated for antiphospholipid antibody, homocysteine, factor V5, 6, 56. 
 
               Extensive tests are not cost effective for all patients who 
present with a thromboembolic event. For patients presenting with venous 
thrombosis, the criteria for undergoing a prothrombotic work up will be one or 
more of the following: recurrent thrombosis, family history of thrombosis, 
thrombosis at young age, thrombosis in locations other than deep veins of the 
leg. 5, 6 
 
For patients with arterial thromboembolism, the indications for a 
complete thrombotic workup will be one or more of the following: young age, 
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multiple thrombotic events, thrombosis in the absence of obvious 
atherosclerosis and when the patient has both arterial and venous thrombosis5 
 
ANTIPHOSPHOLIPID ANTIBODY SYNDROME 
 
Antiphospholipid antibodies are a family of autoantibodies that are 
directed against antigens that are composed of negatively charged 
phospholipids, phospholipid binding protein or both7,23. Clinically important 
antiphospholipid antibodies are lupus anticoagulant and anticardiolipin 
antibody32. Antiphospholipid antibodies have been associated with a number of 
disorders that include arterial and venous thromboembolism, 
thrombocytopenia, recurrent pregnancy loss, neurologic diseases etc5,23. 
 
  Antiphospholipid antibodies require the presence of plasma 
phospholipid binding protein β2 glycoprotein 1, which is an apolipoprotein 
which binds avidly negatively charged phospholipids and is involved in a 
variety of platelet activation and coagulation 7,4,17,44. The possible mechanism 
of thrombosis in antiphospholipid antibody syndrome could be a result of 
vascular or cellular injury17, 44.  It is stated that it could probably be due to the 
antibodies blocking antithrombotic mechanism like decreased conversion of 
protein C to activated protein C, decreased destruction of factor Vc and VIIIa 
by activated protein C, low plasma protein S6, 7. It can also be due to increased 
platelet reactivity due to either decreased prostacyclin synthesis by endothelial 
27 
 
cells as a result of antiphospholipid antibody inhibhition of phospholipase A2 
or due to antibody induced platelet activation4,7,23,44. Other proposed 
mechanisms are activation of complement7, impaired fibrinolysis due to 
elevated plasminogen inhibhitor, and activation of coagulation by increased 
tissue factor synthesis by endothelial cells5. 
 
Most of the patients with autoimmune or rheumatic disease have 
antiphospholipid antibodies. Common autoimmune diseases associated with 
antiphospholipid antibodies are-SLE, Sjogren syndrome, rheumatoid arthritis, 
autoimmune thrombocytopenic purpura and autoimmune hemolytic anemia7.  
 
The antiphospholipid antibody syndrome may be divided into two main 
categories5,7,44. Primary -when it occurs in patients without any clinical 
evidence of other autoimmune disease. It is called secondary when it is 
associated with other autoimmune diseases like SLE44. Bick5 et al describes an 
entity called antiphospholipid thrombosis syndrome, where lupus 
anticoagulant, anticardiolipin antibodies as well as recently recognized  
subgroups of antiphospholipid antibodies like antibodies against beta-2 –
glycoprotein, antibodies to phosphatidyl serine, phosphatidyl ethanolamine, 
phosphatidyl glycerol , phosphatidyl inositol  and anti-annexin V are included. 
He subcategorises antiphospholipid thrombosis syndrome into three groups 
according to the type of antibody involved-the LA thrombosis syndrome, the 
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ACLA thrombosis syndrome and thrombosis associated with subgroups of 
antibodies.  
 
In 1952 Conley and Hartmann described a coagulation disorder in two 
patients with SLE 5. The patients exhibhited anticoagulant activity by in vitro 
testing, which was manifested by a prolonged clotting time and prothrombin 
time. There also have been patients with systemic lupus eythematosus with 
phospholipid dependant inhibhitors of coagulation17,44 Later in 1963, the term 
lupus anticoagulant was proposed for these antibodies, based on their 
prevelance in SLE17.Approximately 10% patients with SLE harbor lupus 
anticoagulant4,5,6,25. Lupus anticoagulant is seen in malignancies, 
lymphoproliferative disorders, viral infections and also seen in association with 
drugs like - chlorpromazine, procainamide, hydralazine, cocaine and dilantin5. 
Most commonly lupus anticoagulant develops in an otherwise healthy 
individual5. Patients with   lupus anticoagulant are at more risk with thrombosis 
related events than anticardiolipin antibodies38. Most commonly it is associated 
with deep vein thrombosis7,25,38. It is also associated with recurrent miscarriage, 
neuropsychiatric disorders, renal vascular thrombosis, thrombosis of dermal 
vessels4,5,7. Primary LA is more common than secondary LA5. They usually 
have venous thrombosis and pulmonary emboli5,15. A wide variety of veins are 
involved including systemic veins like mesenteric, renal, hepatic etc. Arterial 
thrombosis is also observed in some patients with primary LA syndrome5,6. But 
it is less common than in patients with secondary LA syndrome5. Arteries 
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commonly involved include cerebral, coronary, carotid, aorta and arteries of 
extremities4,5. However, even in secondary LA syndrome, venous thrombosis is 
much more common than arterial thrombosis4,6,7. 
 
Purified LA inhibits calcium dependent binding of prothrombin and 
factor Xa to phospholipids, therefore inhibiting the activity of phospholipid 
complex which is required for the conversion of prothrombin to thrombin6. 
Therefore an abnormality often exists in phospholipid dependant coagulation 
reactions, including prothrombin time, activated partial thromboplastin time 
and Russell’s viper venom test, because the LA is not directed against a 
specific factor, but to phospholipids5,16,30,31,50. The inhibitor doesn’t usually 
exert inhibitory effect after prolonged incubation. This property can be used to 
differentiate between lupus inhibitors and other inhibitors of clotting factors. 
Approximately 15- 25 % of cases can be time dependant so this test is not 
definitive. Multiple assays are in use in many laboratories. Sensitivity of 
activated partial thromboplastin time to the presence of lupus anticoagulant is 
highly dependant on the reagent used6,25,27,30,31. Many patients with LA have 
normal APTT5,6. So this test is not an appropriate screening test for LA. 
 
The screening tests should be sensitive to LA. However the basis of 
sensitivity is still not completely understood. A common concept is that the 
amount of phospholipid in the test system is a critical determinant of 
sensitivity6,30. Tests like kaolin clotting time, dRVVT, dilute APTT, dilute 
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prothrombin time has increased sensitivity because they have reduced amount 
of phospholipids5,6,30.The hemostasis committee of the “socie francaise de 
biologie Clinique” found that some weak to moderate LA’s were detected with 
one but  not another assay5,6. So they suggested that multiple types of sensitive 
assay to enhance the overall sensitivity. Brant et al suggest more than one type 
of assay should be done for screening6. Screening assays for lupus 
anticoagulants suggested by Brant et al is as follows - activated partial 
thromboplastin time, dilute activated partial thromboplastin time, dilute Russell 
viper venom test, dilute prothrombin time, kaolin clotting time, silica clotting 
time6. All of these are phospholipid dependant clotting tests5,6,30. 
 
The scientific subcommittee criteria for diagnosis of lupus 
anticoagulants are the following6: 
 
1.   Prolongation of at least one phospholipid dependant clotting 
tests. 
2.  Evidence of inhibitory activity shown by the effect of patient 
plasma on pooled normal plasma. 
3.  Evidence that the inhibitory activity is dependant on 
phospholipid.  
  LAs must be carefully distinguished from other coagulopathies 
that may give similar laboratory results or may concurrently occur with LAs. 
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Specific factor assays and clinical histories maybe helpful in identifying LAs 
from other diseases5,6. 
 
Anticardiolipin antibodies are associated with thrombosis and 
thromboembolism of arterial and venous systems, recurrent miscarriages and 
thrombocytopenia5,25,44. They are associated with many types of venous 
thrombotic problems including deep venous thrombosis of upper and lower 
extremities, pulmonary embolus, intracranial veins, inferior and superior 
venacava, hepatic veins, portal vein, renal vein and retinal veins5,17,56. Coronary 
arteries, carotid arteries, cerebral arteries, subclavian or axillary artery, brachial 
arteries, mesenteric arteries are the sites of arterial thrombosis associated with 
anticardiolipin antibodies17,56. It is also associated with livido reticularis, 
transient ischemic attacks, small stroke syndrome, valvular heart diseases and 
acute myocardial infarction5. The obstetric complications associated with 
anticardiolipin antibodies are frequent abortion in first trimester due to 
placental thrombosis20 or vasculitis, recurrent fetal loss in second and third 
trimester20, also due to placental thrombosis or vasculitis, and maternal 
thrombocytopenia5,7. The primary phospholipid syndrome often is present in 
patients with a constellation of concomitant arterial occlusions, strokes, 
transient ischemic attacks leading to multiple infarct dementia, deep vein 
thrombosis associated with pulmonary embolization and resultant pulmonary   
hypertension, recurrent miscarriage5,7,18,20,25. Anticardiolipin antibodies have 
been reported in patients with  HIV  infection7, however there is no correlation 
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between antiphospholipid antibody level and disease progression  or incidence 
of thrombosis. Elevated anticardiolipin antibodies are seen in a number of acute 
infections like-varicella, rubella, Lyme disease, mycoplasma, certain drugs like 
procainamide, cocaine, phenytoin which may  progress to a prothrombotic 
disorder sometimes5,44. 
 
              The antiphospholipid thrombosis syndrome associated with 
anticardiolipin can be divided into 6 subgroups depending on the site of 
thrombus formation5. The detection of anticardiolipin antibody is by ELISA-
36% have isolated IgG, 17% IgM, 14% IgA, 33% mixture of all5,7. So it is 
better to measure all three antibodies. 
 
International consensus statement   gives clinical and laboratory criteria 
for the diagnosis of antiphospholipid antibody syndrome38,44.  
 
Clinical criteria is as follows:44 
 
1. One or more clinical episodes of arterial, venous or small vessel 
thrombosis occurring within any tissue or organ.  
2. One or more unexplained deaths of morphologically normal 
fetuses at or after the tenth week of gestation; or one or more premature births 
of morphologically normal neonates at or before 34th week of gestation; or 
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three or more unexplained consecutive spontaneous abortion before tenth week 
of gestation. 
 
Laboratory Criteria: 
 
1. Anticardiolipin antibodies IgG or IgM at moderate or high levels 
in the blood on two or more occasions at least six weeks apart. 
2. Lupus anticoagulant antibodies detected in blood on two or more 
occasions at least six weeks apart7,44. 
 
     Therefore, the hallmark laboratory result which defines an 
antiphospholipid antibody syndrome is the presence of antiphospholipid 
antibody detected by phospholipid dependents tests of coagulation44. Steven et 
al suggests that in a suspected case of antiphospholipid antibody syndrome, 
anticardiolipin antibodies, anti beta -2 glycoprotein 1 antibodies, activated 
partial thromboplastin time, lupus anticoagulant by DRVVT, tests for syphilis 
(false positive) as well as a complete blood count should be done, complete  
blood count reveals thrombocytopenia and Coomb’s positive hemolytic 
anemia7.  
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 ELEVATED FACTOR VIII LEVELS AND THROMBOSIS. 
 
  Elevated plasma factor VIII level is associated with recurrent 
venous as well as arterial thromboembolism.  Several prospective studies in 
healthy individuals shows an association between elevated factor VIII:C levels  
and von Willebrand factor levels  and the incidence of ischemic heart 
disease33,39.  In a study by Leiden Thrombophilia it was observed that 
individuals with levels of factor VIII :C  exceeding 150 IU/dl  had a three fold 
increased risk  compared with those with levels lesser than 150 IU/dL33,39,42. 
However, the cause of elevated factor VIII: C, which is an acute phase reactant 
is still not completely understood. 
 
There is a genetic influence on the level of factor VIII: C. It has been 
suggested that a primary role of X linked genetic determinants on the basis of 
observation of positive correlation of factor VIII:C levels within  groups of 
male pairs who had identical X alleles. von Willebrand factor and blood group 
are important determinants of factor VIII level in the plasma12,33. Non O blood 
group is associated with higher von Willebrand factor and factor VIII levels 
than in blood group O33. Individuals with AB blood group have highest von 
Willebrand factor levels. Blood group A, B and H oligosaccharide structures 
have been identified on vWF/factor VIII complex33,39.  
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              Since factor VIII:C is elevated in response to acute phase 
reaction5,12,42. It is difficult to determine whether increased factor VIII: C 
precedes thrombosis or whether it is a secondary reactive phenomenon. 
Kamphausein et al opines that elevated factor VIII levels in patients with 
thrombosis persist over time39. So they possibly are not caused by acute-phase 
reactions. O’Donell et al showed that only 50% of persistently elevated  factor 
VIII levels were associated with high vWF:Ag levels, indicating that   von 
Willebrand factor is not always responsible for high factor VIII plasma levels37. 
However some authors  recommend  that  if a patient presenting with 
thrombophilia has elevated factor VIII levels, shortly after the thromboembolic 
event, the test should be repeated after two or three months33,39.  
 
The cause of elevated factor VIII:C levels in the plasma in a 
thromboembolic event is not properly understood. It was observed that factor 
VIII C, even several months after the acute thrombotic event were elevated25,27. 
Furthermore the correction for C-reactive protein and fibrinogen-well known 
acute phase proteins did not alter the observed odd ratios. So an acute phase 
response is ruled out. Consistent elevation of factor VIII C supports the notion 
that it is the intrinsic factor VIII:C levels which is responsible for the 
association with venous thromboembolism12,37,42. Another possibility is that 
high plasma concentration of factor VIII C is partially determined by genetic 
factors39. Kamphausein et al noted a high concordance of factor VIII levels 
between first degree relatives of patients with thrombosis with high factor VIII 
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levels. No variations in factor VIII or vWF gene that are associated with high 
factor VIII levels have been observed. High levels of factor VIII are likely to 
be expressions of “gain in function mutation”42.  
 
Other determinants of plasma factor VIII levels are body mass index, 
high levels of blood glucose, insulin, fibrinogen and triglycerides. It is also 
observed that factor VIII levels increase with age25, with an average rise of 5 to 
6 IU /dl per decade. Exercise transiently induces a rise in factor VIII levels. 
This may probably be a result of adrenaline stimulation 12. Sustained rise in the 
plasma factor VIII levels are seen during pregnancy, surgery, chronic 
inflammation, malignancy, liver disease, hyperthyroidism, intravascular 
hemolysis and renal disease12,25,39. 
 
In a study based on venous thrombosis by Leiden Thrombophilia , non 
O blood group, von Willebrand factor: Ag, and factor VIII:C were all 
associated with an increased risk for venous thrombosis by univariate analysis. 
In multivariate analysis factor VIII: C levels were consistently elevated in 
patients with thrombosis, but the effect of blood group and vWF:Ag on 
thrombosis were almost disappeared12,22,27,49. This suggests that factor VIII is 
an independent risk factor for venous thrombosis and that vWF and blood 
group are only risk factors in so far as they affect the factor VIII level. As 
mentioned earlier, factor VIII levels >150 IU /dl is at high risk for developing 
thrombosis16,19,21. Each increase in factor VIII level of 10 IU/dl is associated 
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with a 10% increase in the risk of a first thrombotic event.12,39.  For recurrent 
disease this figure is 24%, showing that elevated factor VIII is an even stronger 
risk for recurrent disease22. In previous studies antigen method was used for 
factor VIII assay, but one stage clotting assay was also found to have equal 
results 22. But Wells et al opines that these values do not identify patients at risk 
of recurrence 54. He also suggests that age and gender should also be 
considered before the  labs establish factor VIII levels that identify risk for 
venous thromboembolism  49,54. 
 
Determining patients with elevated levels of factor VIII   that attribute to 
venous thromboembolism may be important for family risk evaluation. There 
are evidences that there is an independent genetic cause for persistently 
elevated factor VIII levels and a quantitative locus on chromosome 18 54. 
Genetic alterations that correlate with elevated levels of factor VIII were not 
identified, but heritability has been demonstrated 54. Therefore determination of 
elevated factor VIII levels in patients with venous thromboembolism should 
lead to consideration of screening of first degree relatives 18 54. 
    
Less commonly elevated factor VIII levels are seen in arterial 
thrombosis. The first reports on a possible association between factor VIII and 
coronary artery disease  was in 1960”s 17.In the same period , non O blood and  
von Willebrand factor were identified as candidate risk factors for 
atherothrombotic disease 22,33,39. Several studies have shown association 
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between elevated factor VIII levels and vWF levels with ischemic heart 
disease33,39. 
 
Meade et al found that factor VIII remained associated with ischemic 
heart disease after adjustment of blood group, without taking vWF  into 
account33. In the Hoorn study, high von Willebrand factor levels were 
associated with cardiovascular mortality independent of blood group in diabetic 
and non diabetic subjects 33. When vWF and factor VIII are mutually adjusted 
for, neither of the two remained associated with coronary artery disease. 
Therefore, it is likely that factor VIII and vWF increase the risk of arterial 
thrombosis and this is independent of blood group33. Meade et al suggested that 
factor VIII is associated with ischemic heart disease, perhaps as a marker of 
vessel wall changes exerted by vWF antigen and factor VIII: C contributing to 
the degree of coagulability33. 
 
  The ARIC study demonstrated strong association of factor VIII and 
vWF with risk factors for atherosclerosis such as hypertension, diabetes 
mellitus, body mass index and triglycerides. Some of these factors are known 
to be associated with perturbed endothelial and vascular inflammation. High 
shear forces, like those in stenosed vessles, increase vWF secretion by vascular 
endothelium and thus will stimulate platelet adhesion and aggregation at the 
site of damaged arterial walls, which may lead to thrombus formation12,39. This 
explains the elevation of factor VIII levels in stroke patients with presumed 
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large vessel disease39. High factor VIII levels may stimulate formation of 
thrombin and thus result in increased platelet activation and fibrin formation39. 
Past studies have found that there is low cardiovascular mortality in hemophilia 
patients. This also supports that elevated factor VIII levels are associated with 
arterial thrombosis33,39,42.  
 
SICKLE CELL DISEASE AND HYPERCOAGULABILITY 
 
           Sickle cell disease is an inherited disorder characterized by the 
presence of sickle hemoglobin, which results from the substitution of glutamic 
acid by valine at the sixth position of the beta globin chain.  These patients will 
have hemolytic and vaso occlusive crisis, which is well known for years. 
Recently it was found that these patients are at risk for a variety of thrombotic 
complications2. Ischemic stroke due to occlusion of large vessel and 
superimposed thrombosis occurs commonly in patients with sickle cell 
anemia14. It has also been reported that it is associated with pulmonary 
embolism, deep vein thrombosis and several events of venous thrombosis 2. 
 
           Sickle cell disease affects several components of hemostasis like, 
platelet function and the procoagulant, anticoagulant and fibrinolytic system. 
Hence it is often called as a hypercoagulable state 2,17. Red blood cells have 
phosphatidyl serine in inner monolayer of the cell membrane, and 
phospholipids in the outer monolayer in the plasma membrane. RBC 
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membrane asymmetry is maintained by the action of an ATP-dependant 
aminophospholipid translocase45. This is lost in sickle cell disease. Abnormal 
phosphatidyl serine exposure occurs as a result of sickling and unsickling 
which results in production of terminal spicules  with exposed phophatidyl 
serine. This abnormal external exposure of phosphatidyl serine alters the 
hemostatic properties of RBC’s which lead to thrombosis2,17,45. 
 
            The Tissue factor-factor VIIa complex is the initiator of 
hemostasis2. In sickle cell disease abnormal expression of tissue factor by 
endothelial cells have been observed2,45. This expression is increased during 
pain crises2. It is found that sickle circulating endothelial cells abnormally 
express tissue factor antigen2. In sickle cell disease tissue factor procoagulant 
activity is also elevated17. Thrombin, interleukin -1, tumor necrosis factor and 
endotoxin can increase tissue factor expression. These are found to be 
increased in sickle cell disease2. The possible mechanisms that would lead to 
increased tissue factor expression are ischemia-reperfusion injury and increased 
hemolysis of type II phosphatidyl positive cells27,32.  
 
       Patients with sickle cell disease have increased plasma levels of 
markers of thrombin generation in non-crisis steady state2,32. F1.2, TAT 
complexes, D - dimers, PAP complexes and fibrinopeptide A are seen in sickle 
cell disease in the non crises state. Decreased levels of natural anticoagulant 
proteins are detected in patients with sickle cell disease.  Thus levels of protein 
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C and protein S are decreased in sickle cell disease. Reduced levels of these 
regulatory proteins may be a consequence of chronic consumption due to 
increased thrombin generation resulting from intravascular tissue factor 
expression and RBC prothrombinase activity. It may also be due to increased 
binding of protein S by sickle RBC or it may be the result of inhibition of 
binding of protein S to beta 2 glycoprotein 1by antiphospholipid antibodies. 
Anti phospholipids antibodies are also elevated in sickle cell disease2. 
 
                It has been suggested that the circulating platelets in patients 
with sickle cell disease are chronically activated2. This also contributes to 
hypercoagulability in sickle cell disease. Platelet aggregation studies have 
found increased responses in adult patients with sickle cell disease in the non 
crises state2. This may be due to increased number of circulating active 
platelets or increased levels of thrombin, ADP, and epinephrine, which are 
platelet agonists32. 
 
MYELOPROLIFERATIVE DISORDERS AND THROMBOSIS 
 
 Myeloproliferative disorders are a group of disorders which are 
characterized by proliferation of blood cells17,23. The myeloproliferative 
disorders commonly associated with thromboembolism are essential 
thrombocythemia, polycythemia rubra vera and myelofibrosis with myeloid 
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metaplasia23,32. However chronic granulocytic leukemia is not associated with 
thromboembolism.  
 
        It has been suggested that thrombotic event in myeloproliferative 
disorders are platelet mediated, rather than pathologic activation of coagulation 
or insufficient fibrinolysis14. Even though the myeloproliferative disorders are 
accompanied by thrombocytosis, abnormal function of platelets appears to be 
the cause of vascular occlusion14. Reduced alfa adrenergic receptors in the 
platelets, decreased number of delta granules, decreased membrane 
procoagulant activity, reduced lipoxygenase activity are seen in 
myeloproliferative disorders, but which of these is responsible for arterial and 
venous thrombosis is not clear14. Alterations of platelet and megakaryocytic 
structure is seen in essential thombocythemia14,32. But studies have failed to 
relate these structural changes to an increased risk for thrombosis. Studies of 
platelet function have largely failed to define correlative abnormalities that 
could be used to define the risk for thrombosis. It was found that there is 
significant platelet hyperactivity in patients with essential thrombocythemia 
with thrombosis14. High blood viscosity due to high hematocrit may also be the 
cause of thrombosis in myeloproliferative disorders 17.  
              
  Thrombosis in myeloproliferative disorder can involve almost all 
levels of vascular tree including peripheral or abdominal veins, large arteries 
and arterioles 14,17,32. Hepatic veins, mesenteric veins and splenic veins have 
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been found to have increased predisposition to thrombosis in 
myeloproliferative diseases 52. Myocardial infarction, peripheral artery 
thrombosis, eythromelalgia, retinal artery occlusion and transient ischemic 
attacks are the manifestations of arterial and arteriolar thrombosis in 
myeloproliferative disease14,23,52..The laboratory diagnosis of a 
myeloproliferative disorder can be made when a patient has elevation of 
peripheral counts, splenomegaly and hypercellularity of the marrow. In some 
instances there may not be any significant clinical features and peripheral blood 
also shows only mild elevation in counts, slightly abnormal platelet 
morphology. In such cases, a peripheral blood or bone marow erythroid colony 
assay will help in correct diagnosis 17,23,52. 
 
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA  
 
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell 
disorder characterized by complement mediated hemolysis, hypercoagulability 
and bone marrow failure1. The disease may be of autoimmune origin. It is an 
intrinsic erythrocyte disorder. It is the result of an aquired stem cell somatic 
mutation1,17,23,51,52. The abnormal stem cell clone produces rbc’s, platelets and 
neutrophils that bind abnormally large amount of complement that are 
abnormally sensitive to complement lysis.  This disorder is characterized by 
increased sensitivity to complement mediated lysis and is responsible for many 
manifestations of this disease-intravascular hemolysis with or without gross 
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hemoglobinuria, pancytopenia or aplasia, increased sensitivity to infections and 
venous thrombosis. These patients are prone to venous thrombosis  peripheral 
veins,  abdominal veins  and cerebral veins are also  involved1,30,32,51,52.  
 
   PNH was first described as a distinct clinical entity in 1882. The 
cardinal diagnostic test, introduced in the late 1930s, is Ham's test, which is 
based on the increased sensitivity of PNH-affected erythrocytes to lysis by 
complement10. Deficiency of an antigen known as the membrane inhibitor of 
reactive lysis (CD59) is largely responsible for the hemolysis and is implicated 
in the tendency for patients to have thrombosis 46. In the past two years the 
biochemical defect underlying PNH has been  pinpointed at an early step in the 
biosynthesis of glycosyl phosphatidylinositol molecules — namely,  the 
transfer of N-acetylglucosamine to phosphatidylinositol.The protein required 
for this step  is encoded by a gene, PIG-A, that is somatically mutated in 
patients with PNH46,51.  
 
The product of the PIGA gene is required for the biosynthesis of a 
glycolipid anchor that attaches a class of membrane proteins known as glycosyl 
phosphatidyl inositol (GPI) – anchored proteins to the cell surface. The absence 
of GPI-anchored proteins leads to complement- mediated intravascular 
hemolysis, because 2 important complement regulatory proteins (CD55 and 
CD59) are missing from PNH cells23. Hemolysis in PNH occurs 
intravascularly. This leads to release of free hemoglobin, a potent nitric oxide 
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scavenger. Depletion of nitric oxide at the tissue level contributes to fatigue, 
esophageal spasm, thrombosis, and male erectile dysfunction1. 
 
Thrombosis—the leading cause of death in PNH—occurs in up to 40% 
of patients1,51. Patients with a large PNH cell population (>60% of 
granulocytes) seem to be at greatest risk for thrombosis. The mechanism of 
thrombosis in PNH is not entirely understood and is probably multifactorial; 
however, it must also relate to the GPI anchor protein deficiency. Nitric oxide 
depletion is associated with increased platelet aggregation, increased platelet 
adhesion, and accelerated clot formation1. In an attempt to repair the damage, 
platelets in patients with PNH undergo exocytosis of the complement attack 
complex, leading to formation of microvesicles lined with phosphatidylserine 
on their external surface. Phosphatidylserine is a potent procoagulant that is 
normally confined to the inner leaflet of the plasma membrane; the circulating 
microvesicles from PNH platelets activate coagulation and probably contribute 
to thrombophilia in PNH17,23,51.  
 
ACTIVATED PARTIAL THROMBOPLASTIN TIME AND 
THROMBOSIS 
 
Activated partial thromboplastin time (aPTT or APTT) is a performance 
indicator measuring the efficacy of both the "intrinsic" and the common 
coagulation pathways 31. Apart from detecting abnormalities in blood clotting, 
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it is also used to monitor the treatment effects with heparin, a major 
anticoagulant used in clinical practice. It is used in conjunction with the 
prothrombin time (PT) which measures the extrinsic pathway10. Prolonged 
APTT may indicate use of heparin, antiphopsholipid antibody or a coagulation 
factor deficiency10,56. A shortened APTT may indicate elevated coagulation 
factor levels31. 
 
 As discussed previously, hypercoagulability may be due to defective 
naturally occurring anticoagulant mechanisms or due to increased levels of 
procoagulant factors. Increased levels of coagulation factors like factor VIII, 
IX, XI and fibrinogen is associated with thrombophilia30,31. These factors 
belong to classical intrinsic pathways of coagulation, which can be 
cumulatively explored by activated partial thromboplastin time50. 
 
Tripodi et al suggests that a shortened activated partial thromboplastin 
time reflect the procoagulant imbalance consequent to increased levels of 
coagulation factors and hence it shows an association with an increased risk  of 
venous thromboembolism50. Activated partial thromboplastin time is a test 
which gives an overview of all coagulation factors except factor VII32. Hence  
it is a suitable test to reflect the procoagulant imbalance resulting from 
increased levels of single coagulation factors, which are found to be risk factor 
in previous studies. Tripodi et al found that patients with shortened APTT were 
at high risk for venous thromboembolism50. Previous studies also shows that 
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recurrence of venous thromboembolism can be predicted by doing APTT and it 
was found that recurrence is associated with a shortened aptt16. APTT is a 
global test responsive to plasma levels of coagulation factors of contact, 
intrinsic and common pathways16,50. Elevated levels of some of these 
coagulation factors have been identified as independent risk factors of venous 
thromboembolism. Tripodi  et  al’s study showed that when levels of factor 
VIII was taken as confounding variable, the relative risk of venous 
thromboembolism associated with shortened APTT decreased to 2 fold, but 
remained statistically significant16,50. This indicates the high levels of factor 
VIII are not the only determinants of shortened APTT. 
 
Shortened APTT have been associated with high levels of biochemical 
markers of thrombin generation and fibrin deposition such as prothrombin 
fragment 1+2, thrombin –antithrombin complex and D-dimer. It has also been 
found that patients with shortened APTT have a poor prognosis for 
thrombosis40. 
 It has also been reported that lupus anticoagulant, recent thrombosis, 
liver disease and pregnancy affect   activated partial thromboplastin time. 
Lupus anticoagulants are often clinically noticed by unexplained prolongation 
of APTT44. APTT is most frequently employed as the initial screening test in 
lupus anticoagulant55. Its specificity can be improved by inclusion of a mixing 
study with platelet free normal pooled plasma. When prolongation of APTT is 
due to coagulation factor deficiency, the clotting time corrects.  
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                             RESULTS 
 
In this study, 310 cases were analysed to identify the risk factors of 
thrombosis.  Blood samples were collected from patients presenting to various 
departments of PSG Institute of Medical Sciences and Research with a 
thrombotic tendency. Lupus anticoagulant, anticardiolipin   antibody,  Factor 
VIII assays, prothrombin time, activated partial thromboplastin time, sicklevue 
test, Ham’s test and sucrose  lysis test were done on these samples. 
 
CLINICAL PROFILE OF THE CASES ANALYSED 
 
124 patients had presented with proximal and distal venous thrombosis 
(41.3%).68 patients had recurrent abortions (22.6%). 38 cases(12.7% ) had  
presented with ischemic heart disease. 43 cases had presented with 
cerebrovascular diseases. (14.3%). There were 11 cases of vasculitis (3.6%), 10 
cases of arterial thrombosis and 16 cases of pulmonary thromboembolism 
(5.3%) 
 
ANALYSIS OF RISK FACTORS IN DIFFERENT THROMBOTIC 
DISEASES 
 
1.  Venous thrombosis –proximal and distal: 
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124 patients had distal and proximal venous thrombosis. (41.3%) 
Majority of the patients had deep vein thrombosis of posterior tibial vein 
(29%). 8 % patients had multiple deep vein thrombosis. Multiple deep vein 
thrombosis was more common in intraabdominal veins. Deep vein thrombosis 
of axillary veins, portal veins, splenic veins and superior mesenteric veins were 
also studied. 
 
            Antiphospholipid antibody (LA& or ACA) was positive in 24 
cases (19%). Increased factor VIII:C levels were observed in 37 
patients(29.9%). 18 cases showed elevated factor VIII levels as well as 
antiphospholipid antibodies. Shortened APTT was present in 13 cases (10.5%). 
All risk factors were negative in 60 cases (54.8%). 
          
         An 18 year old female patient presented with multiple deep vein 
thrombosis of internal jugular vein, bilateral brachiocephalic, bilateral 
subclavian and partial thrombosis of inferior venacava. The patient had a 
prolonged prothrombin time of 27 seconds which was corrected to 12 seconds. 
Activated partial thromboplastin time was 31 seconds. Lupus anticoagulant was 
29 seconds, IgG was 5GPLU/ml, IgM was 5.8 MPLU/ml. This patient had an 
elevated factor VIII levels of 200 %. Another patient with elevated factor 
VIII:C level was a 30 year old lady, who had developed axillary vein 
thrombosis. Her APTT, lupus anticoagulant assay, anticardiolipin antibodies, 
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sickle test, and Ham’s test were within normal limits. Prothrombin time was 
prolonged to 25 seconds, but on correction it was 13 seconds. 
 
      A 32 year old lady had multiple deep vein thrombosis of both 
lower limbs. Lupus anticoagulant was positive and factor VIII was elevated in 
this patient. Lupus anticoagulant assay showed 67.8 seconds for screen and 
51.9 seconds for confirm. Ratio was 1.3. Factor VIII level was observed to be 
200%. 
 
      A 37 year old male had multiple deep vein thrombosis of lower 
limbs- posterior tibial vein, anterior tibial vein, saphenous vein and pulmonary 
embolism. All tests were normal except for a shortened APTT of 24 seconds. 
 
        A male of 54 years had come with intermittent episodes of 
hemoglobinuria. Ultrasound abdomen showed portal vein thrombosis. He had 
all tests normal, except a positive Ham’s test and sucrose lysis test. That was 
the only case with paroxysymal nocturnal hemoglobinuria. 
 
2. Pulmonary venous thromboembolism: 
  
16 cases of pulmonary thromboembolism were analysed. None of them 
showed positive antiphospholipid antibodies. Increased factor VIII levels were 
observed in 8 cases (50%). Shortened APTT was observed in 3 cases (18.75%). 
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Increased factor VIII :C and shortened APTT was seen in 2 cases(12.5%). 
Sicklevue test was positive in a case (6.25%). All risk factors were negative in 
6 cases (37.5%). 
 
  A 22 year old lady had presented with pulmonary embolism.  She 
had moderate anemia, peripheral smear showed a mild hemolytic picture,    
with occasional sickle like  RBC’s. Sicklevue test was positive (heterozygous). 
Even a sickle test was done and was found to be positive. Only this case 
showed positivity for sicklevue test in the entire study.  
 
   A 23 year old lady had presented with pulmonary venous 
thromboembolism, showed shortened APTT of 23 seconds and elevated factor 
VIII levels of 200%. Another patient who had shortened APTT of 22 seconds 
and elevated factor VIII levels of 200%, was a 63 year old male patient with 
pulmonary embolism. 
 
3. Arterial thrombosis: 
 
10 cases of arterial thrombosis were studied. The cases were of superior 
mesentric artery thrombosis, subclavian artery thrombosis and pulmonary 
artery thrombosis. Antiphospholipid antibodies were positive in 3 cases (30%). 
Increased factor VIII :C levels were seen in 2 cases (20%). All risk factors 
were negative in 5 cases (50%). 
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RISK FACTORS ANALYSIS 
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Risk Factors Analysis in Venous Thrombosis - Proximal & Distal 
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Ischeamic  Heart Disease 
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   A 42 year old man had presented with ischemic bowel disease, ultrasound 
abdomen showed thrombosis of celiac and superior mesenteric artery. This 
patient had negative results for all the tests we did in the study, except for an 
elevated factor VIII level of 200%. 
 
A 41 year old lady had presented with pain and edema of left upper 
limb and subclavian artery thrombosis, had antiphospholipid antibodies 
positive. Her lupus anticoagulant screen test showed a value of 68 seconds, 
confirm results of 70 seconds and ratio of 1.1. Her IgG value was 18 
GPLU/ml and IgM value was 17 MPLU/ml. All other tests done in this study 
were within normal limits. 
 
A 4 year old girl had idiopathic pulmonary hypertension and 
pulmonary arterial thrombus. On analysis, lupus anticoagulant and 
anticardiolipin antibodies were positive. Lupus anticoagulant screen value was 
58.1 seconds and confirm value was 43 seconds, the ratio was 1.2. 
Anticardiolipin assay showed IgG levels of 18.2 GPLU/ml and IgM levels of 
22.1 MPLU/ml. Factor VIII level was normal. This patient was the youngest 
patient in the study. 
 
4. Ischemic heart disease: 
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  38 cases of ischemic heart disease were analysed in this study. 
There were cases of myocardial infarction and acute coronary syndrome. 
Antiphospholipid antibodies were positive in 11 cases (28.6%). Increased 
factor VIII:C was seen in 9 patients (23.7%). All risk factors were negative in 
rest of the 18 cases.(71.4%)  
 
       A 27 year old male patient presented with acute coronary 
syndrome. His prothrombin time was prolonged, but corrected prothrombin 
time was normal. APTT was 30 seconds. Lupus anticoagulant assay screen 
test was 60.1 seconds and confirm test was 56 seconds and the ratio was  1.1, 
which indicates a positive result for lupus anticoagulant assay. Anticardiolipin 
antibodies were also positive in this patient. IgG level was 20 GPLU/ml and 
IgM level was 22.1 MPLU/ml. Factor VIII level was in the upper limit of 
normal, i.e 149%.  
 
            A 25 year old male had presented with myocardial infarction. 
All the investigations done in this study were normal except for increased 
factor VIII level of 200%. 
 
5. Cerebrovascular Diseases 
 
There were 43 patients with cerebrovascular diseases like superior 
sagittal sinus thrombosis, as well venous and arterial infarcts in the brain 
58 
 
parenchyma. 16 patients (37.2%) had antiphospholipid antibodies (either 
lupus anticoagulant or anticardiolipin antibodies or both.). Increased factor 
VIII levels were seen in 22 cases (50%). Shortened APTT was seen in 11 
cases. All these cases had antiphospholipid antibodies positive. Out of this, 5 
patients (12.5%) had increased factor VIII levels as well. All risk factors were 
negative in 10 patients (23.3%).  
            
 A 63 Year old female presented with superior sagittal sinus 
thrombosis. Her activated partial thromboplastin time was shortened i.e 24 
seconds, and antiphospholipid antibodies were positive. Lupus anticoagulant 
screen test was 72.6 seconds and confirm time was 74.6 seconds. The ratio 
was 1.1. Anticardiolipin antibody assay showed IgG to be 28.8 GPLU/ml and 
IgM value of 30.8 MPLU/ml. Factor VIII level was within normal limits. 
 
A 67 year old male had infarct in the left corona radiata and lacunar 
infarcts in thalamus. His APTT was shortened with a value of 23 seconds. 
Lupus anticoagulant screen time was 62 seconds, and confirm time was 50 
seconds, the ratio was 1.2. which indicates a positive result for lupus 
anticoagulant. Anticardiolipin antibodies were positive. IgG level was 23 
GPLU/ml and IgM level was 23 MPLU/ml. Factor VIII was also elevated in 
this patient with a factor VIII level of 200%. 
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6. Recurrent abortions 
 
Women referred to the obstetrics department with a history of early, 
recurrent abortion (at least three pregnancy losses before 13 weeks of 
gestation) were eligible to be included in this study. Exclusion criteria were 
endocrine, immunological or anatomical causes of embryo demise. 68 cases of 
recurrent abortion were included in this study. 19 cases (27.3%) were positive 
for either lupus anticoagulant or anticardiolipin antibody or both. Increased 
factor VIII levels were seen in 25 cases (36.4%). 12 cases (18%) showed 
positivity for antiphospholipid antibodies as well as elevated factor VIII level. 
All risk factors were negative in 36 cases (52.9%).  
 
7. VASCULITIS 
 
11 cases of vasculitis were included in the study. 6 patients had 
elevated factor VIII levels (54.5%). All risk factors were negative in rest of 
the 5 cases (45.5%) 
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DISCUSSION 
 
The epidemiology of venous thromboembolism (VTE) in the 
community has important implications for the prevention and management of 
this disease. In order to improve survival, avoid recurrence and prevent 
complications, the occurrence of VTE must be reduced.  To reduce the 
incidence of VTE, persons at risk for thromboembolism must first be 
identified.  Independent risk factors for VTE include patient age, surgery, 
trauma, hospital confinement, active malignancies, neurological diseases and 
procedures like central vein catheterization. Recent family based studies 
indicate that VTE is highly heritable and follows a complex mode of 
inheritance involving environmental interactions18. Inherited reductions in 
plasma natural anticoagulants – antithrombin, protein C, protein S -have long 
been recognized as uncommon but potent risk factors for VTE. More recent 
discoveries of impaired down regulation of the procoagulant system like 
Activated Protein C resistance, Factor V Leiden15 and increased plasma 
concentrations of procoagulant factors such as factors I, II, VIII, IX, and XI19 
have added a new dimension to the list of inherited or acquired disorders 
predisposing to thrombosis19,35.  
 
The identification of risk factors for thrombosis is a controversial topic. 
However, such studies should help identify a vulnerable population and help 
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target prophylaxis to those who benefit the most and ultimately reduce the 
occurrence of VTE.   With the above objectives in mind, 310 patients with 
symptomatic venous or arterial thrombosis were evaluated to identify the 
possible etiology of the thrombosis. Patients were classified according to their 
underlying disease syndrome. The major categories included patients having 
proximal or distal venous thrombosis (40.0%). 68 patients who attended the 
obstetrics out patient department with history of recurrent abortions were 
included in this study (21.9%). Other thrombotic events included CNS arterial 
thrombosis (13.9%), coronary artery disease and myocardial infarctions 
(12.3%), pulmonary embolism (5.2%) and vasculitis (3.5%) and arterial 
thrombosis (3.2%).  
 
The investigations done included coagulation tests (prothrombin time, 
activated partial thromboplastin time), factor VIII:C (one-stage APTT based), 
lupus anticoagulant (dRVVT based), anticardiolipin antibodies, acidified 
serum test and sickling test.  
 
Increased factor VIII:C was the commonest risk factor identified 
(32.3%), followed by antiphospholipid antibody (23.5%) and shortened APTT 
(8.7%). No risk factors were identified in 50.6% of the cases. 15.5% of the 
cases had multiple risk factors positive – positive APL with increased factor 
VIII:C, increased factor VIII:C and shortened APTT, and in 12.5% of the 
patients who presented with cerebrovascular symptoms had a combination of 
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APL  positivity together with increased factor VIII:C levels and shortened 
APTT.  
There was one case each of sickle cell anemia and paroxysmal 
nocturnal hemoglobinuria who presented with pulmonary embolism and portal 
vein thrombosis respectively.  
 
ANTIPHOSPHOLIPID ANTIBODIES 
 
Antiphospholipid antibody syndrome is an important clinical entity 
with a strong tendency for thrombosis accompanied by high morbidity and 
mortality. The diagnosis is made when arterial or venous thrombosis or 
recurrent pregnancy failure occurs in a patient with a persistently positive 
laboratory test result for an antiphospholipid antibody – lupus anticoagulant 
&/or anticardiolipin antibody. 
 
In the study done, 23.5% of patients who presented with venous 
thrombosis were positive for antiphospholipid antibodies – lupus 
anticoagulant &/or anticardiolipin antibodies. This incidence is similar to that 
of Steven et al who found the occurrence rate of antiphospholipid antibodies 
in venous thrombosis to be 24%7.  Paul E. Love and colleagues had similar 
results (45%)25. Petri et al and Fort et al had 11% and 31% respectively of 
patients with positive anticardiolipin antibodies25. Bhattacharya et al had 40% 
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patients with positive antiphospholipid antibodies associated with 
thrombosis4. The study done by Pengo et al showed LA and /or anticardiolipin 
antibodies positive in 34% of patients with thrombosis38. 
 
         Literature shows that antiphospholipid antibodies are positive in 
young patients <45 years5,7,25. Most of the studies showed antiphospholipid 
antibodies in age group between 20- 55 years.  In our study, the youngest 
patient was a 4 year old girl with pulmonary arterial thrombosis. 
 
This study has shown positivity for lupus anticoagulant and 
anticardiolipin antibodies in other clinical situations like arterial thrombosis, 
ischaemic heart disease and in patients with recurrent abortions. 34% of the 
patients positive with antiphospholipid antibodies had arterial thrombosis.  
The diagnosis of Lupus anticoagulant followed the criteria set by the 
Subcommittee for the Standardization of Lupus Anticoagulants of the 
International Society of Thrombosis and Haemostasis6. 
  
 Jerrold .S.Levine and colleagues had 27% of patients with LA and or 
anticardiolipin antibodies3,7,44. Bhattacharya et al’s study showed 40% patients 
with lupus anticoagulant with arterial thrombosis4. Paul E Love had 22% 
cases with arterial thrombosis and positive lupus anticoagulant25.  
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Antiphospholipid antibody syndrome has emerged as the most 
important treatable cause of recurrent miscarriage, early onset preeclampsia 
and of intrauterine growth retardation. 27.3% of our patients with recurrent 
pregnancy loss were positive for either lupus anticoagulant or anticardiolipin 
antibody or both. Bhattacharya et al found 22% of patients had recurrent fetal 
loss associated with antiphospholipid antibodies4. Paul E Love has reported 
eight series of retrospective analyses of fetal loss in patients with 
antiphospholipid antibody25. In these studies, the patients who had one or 
more fetal losses ranged from 13 to 58%. Jerrold et al had 20% of patients 
with antiphospholipid antibody presenting with recurrent fetal loss44. 
 
  Anticardiolipin antibodies are not such strong risk factors for 
thrombosis as lupus anticoagulants. Separate analysis of different types of 
thrombosis show that ACA are associated more with cerebral stroke and 
myocardial infarction, and not with DVT27.  In the present study also, it was 
observed that 28.6% and 37.2% respectively of cases of ischaemic heart 
disease and cerebrovascular disease were associated with positive 
anticardiolipin antibodies. Only 19.6% of cases with venous thrombosis were 
positive for anticardiolipin antibodies.  
         
This study did not reveal any statistically significant difference in the 
APL positivity for the following groups of patients – patients with IHD and 
recurrent abortions, patients with venous thrombosis and cerebrovascular 
68 
 
disease and patients with PVTE and vasculitis. In fact, there were no positive 
APL case in this last group of PVTE and vasculitis.  
 
However, the investigation brought out a significant difference in the 
contribution of APL as a risk factor for venous thrombosis when compared to 
pulmonary thrombo-embolism (p=<0.05). The APL positivity seen in venous 
thrombosis was more than what was observed in PVTE. Similarly, there is a 
statistically significant difference in the contribution of APL for PVTE and 
IHD (p=0.003) as well.   
 
According to Ling Zhang et al55. LA testing necessitates investigation 
by at least two or more methods before it is considered negative. In the present 
study, it was observed that 30 patients were positive for only LA, 43 patients 
were positive for ACA and 22 patients showed positivity for both LA and 
ACA.  However there are 237 patients in this study who presented with 
thrombosis and were negative for both tests. Laboratory testing for LAs is not 
standardized, and various combinations of screening, confirmatory and 
integrated test systems can be used. The conventional tests that were used – 
the APTT and the dRVVT, may be insensitive to the presence of LAs, 
necessitating the use of multiple assays before reporting a patient sample as 
negative for LA.  
 
69 
 
The APTT is considered to be a readily available and inexpensive 
screening test for LAs. Zhang et al found only 13 (46.4%) of 28 samples 
testing positive for LAs with a prolonged PTT-LA result 55. The present  study 
did not show prolonged APTT in any of the cases that tested positive for LA. 
From the above findings, the APTT cannot be considered an optimal 
screening test for Lupus anticoagulants. 
 
ELEVATED FACTOR VIII:C 
 
Recently, a growing literature has suggested that elevated levels of 
factor VIII:C may represent a risk factor for VTE  22,37. Coagulation is 
triggered during the onset of myocardial infarction, resulting in vascular 
occlusion. A number of studies have examined the association of 
cardiovascular disease with coagulation factors (fibrinogen, factor VII, factor 
VIII, platelet aggregability) and fibrinolytic factors (tissue plasminogen 
activator, plasminogen activator inhibitor-1, Lp(a) lipoprotein, plasminogen 
activity). Of these, a significant association was seen between increased 
fibrinogen levels and ischemic heart disease. Relatively less is known about 
the relation between factor VIII and cardiovascular disease risk. 
 
In the present study, out of 124 patients who presented with proximal 
and distal venous thrombosis, 29.9% patients had increased factor VIII levels, 
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14.5% had increased factor VIII levels as well as antiphospholipid antibodies. 
Rodereik et al5, and Kyre et al22 had similar results (25%, 27% and 29%). 
O’Donelle’s study also showed 26% cases with elevated factor VIII37. 
Kraaijenhagen et al found high levels of factor VIII in 57% of patients with 
recurrent venous thromboembolism21.  
 
               This study shows a significant association between elevated 
factor VIII:C levels and myocardial disease (23.7%). The presence of elevated 
factor VIII:C levels in PVTE were far more significant than the levels in IHD 
and arterial thrombosis.   
 
A study done by Benchimol et al examined the predictive value of 
haemostatic factors for sudden death in patients with stable angina pectoris3. 
Factor VIII coagulant was found to be a univariate predictor of sudden death 
in this population. In the Northwick Park heart study, mean factor VIII:C 
concentrations were significantly higher in patients who died of ischaemic 
heart disease compared with survivors34. Of 16 cases of pulmonary embolism 
screened in this study, 50% had elevated factor VIII levels. Kamphuisen et al 
report 61% of patients with pulmonary embolism having elevated factor VIII 
levels39. Well’s et al’s study also shows a high number of 51% of patients with 
pulmonary embolism having elevated factor VIII levels54. In their study the 
authors have taken values more than 200 IU/dl as being significant.  
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Factor VIII is an important acute phase reactant, hence the elevated 
levels should be considered significant only if they continue to be abnormal 
several weeks after the thrombotic event. Well’s et al also suggests that age 
and gender should be considered when analyzing factor VIII levels54. 
 
A number of inherited and acquired coagulation abnormalities are 
associated with dural sinus thrombosis. One of the most common and well 
documented of these is the factor V Leiden mutation G1691A seen in 15 to 
20% of cases26. In the present study, there was a significant percentage of 
patients (50%) who presented with superior sagittal sinus thrombosis with 
elevated factor VIII:C levels as well as shortened activated partial 
thromboplastin time.  
 
Known causes or associations of recurrent miscarriage are endocrine, 
immunological, anatomical and genetic causes, although about 50% of cases 
are classifiable as idiopathic. In recent years, attention has to be drawn to the 
possible association of both early and late pregnancy loss with either inherited 
or acquired thrombophilic defects predisposing to the development of DVT, 
namely, FV R506Q (F V Leiden), and prothrombin gene G20210A mutations, 
hyperhomocysteinaemia and antiphospholipid antibodies.  
 
The present study revealed a high association between elevated factor 
VIII: C levels and patients with early recurrent abortions (36.4% of patients). 
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This finding suggests a possible association between this thrombophilic 
condition and early reproductive failure. This data is in concurrence with the 
study by Marietta et al36 in which 25.5% of the patients studied had Factor 
VIII:C levels exceeding the 90th centile of the control population. Dossenbagh 
and colleagues also found 25% of patients with elevated factor VIII levels 
presenting with recurrent abortions13.  
 
It could be hypothesized that hypercoagulable states can lead to some 
vascular impairment in the first phases of embryo implantation. In 
physiological conditions, the F VIII:C concentration rises as pregnancy 
advances. A gradual dose-response relationship between F VIII levels and the 
risk of thrombosis has been observed. Therefore, it can be argued that in 
predisposed women even a small increase in already elevated F VIII:C levels 
can attain a hypothetical threshold required for triggering the thrombotic 
event.  
 
Many acquired variables, above all acute phase reactions may increase 
F VIII:C activity. In order to avoid inflammatory response as a confounding 
factor we should have ideally included measurement of C reactive protein 
(CRP) levels, an established acute-phase marker in all our patients. Given the 
variability of F VIII:C levels due to several pathophysiologic factors, 
however, it remains to be established whether or not FVIII:C levels should be 
included in screening for thrombophilia in such patients. 
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SHORTENED ACTIVATED PARTIAL THROMBOPLASTIN TIME 
 
The activated partial thromboplastin time is a simple coagulation test 
that has been in routine laboratory use for decades. An APTT reagent contains 
suitable concentrations of phospholipid and activator and detects 
coagulopathies of the intrinsic and/or common pathway. If preanalytical 
variables can be excluded, then a shortened APTT could reflect in vivo 
activation and potentially be a marker for thrombosis. 
 
The phenomenon of an abnormal resistance to the anticoagulant 
activity of activated protein C (APC) was first described by Dahlback in 
199311. Dahlback showed evidence for an increased prevalence of APC 
resistance among patients with familial venous thromboembolism. In his 
study, DVT patients with abnormal APC resistance had shorter APTTs than 
those with normal responses to APC. This was just prior to the Factor V 
Leiden being identified (Bertina et al, 1994). Until recently, it was unclear 
whether a link existed between VTE and the phenotype of abnormal APC 
resistance independent of F V Leiden. 
 
The results of investigations associated with the Leiden Thrombophilia 
study53 have shown that non-FV Leiden APC resistance, as quantified in an 
APTT-based screening test, is an independent marker for VTE. Lowe et al24 in 
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attempting to define a preoperative hypercoagulable state that may predict 
postoperative DVT in surgical hip replacement patients assessed the relevance 
of 29 hemostatic factors in 480 patients. Only the shortened APTT and the 
APC resistance ratio showed a statistically significant association with the 
development of postoperative DVT.  
 
McKenna et al31 found that 23% developed VTE in a prospective study 
of 100 medical and surgical patients with shortened APTTs. In the control 
population of medical and surgical patients during the study period, only     
2.2% developed VTE. There was a correlation between the degree of 
shortening of the APTT and the incidence of VTE in this study. 
 
In the present study, 8.7% of cases had shortened APTT. Of these 27 
patients, 16 had venous thrombosis including pulmonary venous thrombosis. 
Two of these patients had in addition elevated factor VIII levels. Out of a total 
of 109 patients with elevated factor VIII:C levels, 27 (25%) had shortened 
activated partial thromboplastin times. 11 patients who had cerebrovascular 
diseases had multiple risk factors– shortened APTT and positive 
antiphospholipid antibody and 5 of these patients, in addition had increased 
factor VIII levels. This indicates that the cause for the low APTT is more 
complex than just increased FVIII levels. 
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Tripodi et al have reported shortened APTT as a risk factor for venous 
thromboembolism with 19% cases with shortened APTT50. This observation is 
supported by the findings of Boekel et al47 and Reddy40. In Tripodi’s study    
83 % of the patients had deep vein thrombosis, 12% with isolated pulmonary 
embolism and 5% with cerebrovascular diseases. He also observed an 
increased factor VIII level with shortened APTT in 27 % of the cases.  
 
It was observed that there was a statistically significant difference in 
the presence of shortened APTT in cerebrovascular disease compared to IHD. 
The literature survey revealed only a single study of a case of fatal dural sinus 
thrombosis associated with a shortened APTT. In this case, factor VIII levels 
were not measured so the basis for the short APTT was unknown8. 
  
SICKLE CELL ANEMIA 
 
Only one of the patients in this study tested positive for sickle cell 
anemia. This patient presented with pulmonary embolism. Stein PD and 
colleagues in a similar study observed deep vein thrombosis to be the 
commonest thrombotic event in sickle cell disease. Austin et al observed 6% 
of cases with sickle cell disease and venous thrombosis. This study however, 
was limited to a black population45. 
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        PAROXYSYMAL NOCTURNAL HEMOGLOBINURIA 
 
A case of paroxysymal nocturnal hemoglobinuria presented with  portal 
vein  thrombosis in our study”. Araten DJ1 and colleagues found 14% of PNH 
patients with venous thrombosis, mostly intraabdominal venous thrombosis. 
Valla D et al 51 and Ziakas et al 58 also have reported a single case of portal 
vein thrombosis in paroxysymal nocturnal hemoglobinuria.  
 
          The present study was limited to only acquired risk factors since at the 
moment, facilities for genetic studies are not available at our institution.  In 
addition, the confirmation of antiphospholipid antibodies as risk factors can be 
done only if repeat testing after a period of 6 weeks is performed.  Only 15 
patients (4.8%) came back for repeat testing. However, their results were 
encouraging since all of them continued to be positive for Lupus 
Anticoagulant and Anticardiolipin antibodies.  
 
Therefore, although this study had significant observations and 
correlations of risk factors for thrombosis, more detailed studies will have to 
be performed   
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SUMMARY AND CONCLUSIONS 
 
The present study was aimed at examining risk factors involved in the 
pathogenesis of thrombosis in the Indian population. Review of literature has 
shown that most of the epidemiology studies to date with reference to 
thrombophilias,  are confined to data derived from the European population.  
 
This study was done on 310 patients who presented with different 
thrombotic disorders. While the clinical utility of diagnostic testing for an 
inherited or acquired thrombophilia remains  controversial,  studies such as 
these hold the potential of further  stratifying individual patients into high- and 
low-risk for incident  and recurrent VTE. This in turn will help target 
prophylaxis to those who benefit the most and ultimately reduce the 
occurrence of venous thromboembolism.    
 
The commonest risk factor identified was increased Factor VIII:C 
levels, followed by antiphospholipid antibody and shortened activated partial 
thromboplastin time. Two hemolytic anemias – one genetic (sickle cell 
anemia) and the other an acquired membrane disorder (paroxysmal nocturnal 
hemoglobinuria) were also found to be associated with a tendency to 
thrombosis. 50% of the patients in this study who presented with thrombosis 
had no identifiable risk factors. 
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The presence of antiphospholipid antibodies was found to be linked 
with ischemic heart disease - myocardial infarction and acute coronary 
syndromes and venous and arterial thrombosis. There was also a very 
significant association between the presence of antiphospholipid antibodies – 
lupus anticoagulant and anticardiolipin antibodies with recurrent abortions. 
Antiphospholipid syndrome has emerged as the most important treatable cause 
of recurrent miscarriage and of intrauterine growth restriction. Though we did 
include a study of 20 control samples in our study in addition to the control 
samples which were run simultaneously with the test samples, there is a need 
to study baseline levels of anticardiolipin antibodies in a larger number of the 
Indian population, to determine at what levels these patients should be treated. 
 
There is abundant evidence that thrombosis is involved in the acute 
presentation of coronary, cerebrovascular, and peripheral vascular diseases. 
Relatively less is known about the relation between factor VIII and 
cardiovascular disease risk. This study showed a significant association 
between elevated FVIII:C levels  and almost all of the thrombotic disorders 
with the highest presence of elevated factor VIII in pulmonary 
thromboembolism.  
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This study has also demonstrated a significantly higher frequency of 
subjects with elevated FVIII:C levels in women with early, recurrent 
abortions.  
 
A shortened APTT has been reported as a risk factor for thrombosis. 
There was a correlation between the shortening of the APTT and the incidence 
of venous thromboembolism in this study. In addition, it was also observed 
that nearly 25% of the patients with elevated FVIII:C levels had shortened 
APTTs.  
 
The study of antiphospholipid antibodies in this study was done with 
two tests – the DRVVT test for LA and the ELISA test for ACA. It is 
important to note that for the diagnosis of antiphospholipid antibody 
syndrome, patients who test LA and ACA negative by the above methods 
must also be tested with other assays for lupus anticoagulant. This study also 
showed that the APTT is not an optimal screening test for detecting lupus 
anticoagulants.  
 
LA may be positive in 1-5% of healthy adults, but none of the control 
samples in this study were positive for LA. 
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It must be stressed that each laboratory should define its own reference 
ranges for all investigations. This study also underlines this fact of the 
importance of locally derived reference ranges.  
 
This study demonstrates that the following categories of patients must 
be tested for risk factors for thrombosis - patients with recurrent idiopathic 
thrombosis, deep vein thrombosis, thrombosis in unusual sites, association of 
arterial and venous thrombosis, recurrent abortions, early age of onset, and 
patients with a family history of venous thromboembolism. The investigations 
must include both acquired as well as genetic factors contributing to 
thrombosis. It is important to stratify patients according to their risk factors in 
order to target primary and secondary prophylaxis to the patients who would 
benefit the most. 
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KEY TO MASTER CHART 
 
ACL -  ANTI CARDIOLIPIN ANTIBODY 
Ant -  ANTERIOR 
C -  CONTROL 
CVA - CEREBROVASCULAR ACCIDENT 
DVT -  DEEP VEIN THROMBOSIS 
IHD -  ISCHEMIC HEART DISEASE 
LA -  LUPUS ANTI COAGULANT 
Lt -  LEFT 
Post -  POSTERIOR 
R -  RATIO 
Rt -  RIGHT 
SMA -  SUPERIOR MESENTRIC ARTERY 
SMV -  SUPERIOR MESENTRIC VEIN 
SSS - SUPERIOR SAGITTAL SINUS 
VTE - VENOUS THROMBOEMBOLISM 
 
